 Part 1 is a double-blind, placebo-controlled, randomised single dose design in up to 64 healthy male subjects. Part 1 will consist of Groups 1 to 6, each comprising 8 subjects total of 48 subjects. There will be an option to enrol 2 additional groups 8 subjects in each of Groups 7 and 8 to assess alternative dose levels. Subjects will be randomised to receive active or placebo in the fasted state. 